NASDAQ · HLN
Healthcare · Drug Manufacturers - Specialty & Generic
$9.32
Up+$0.07 (+0.70%)
Updated Oct 10, 2026, 8:46 PM
SID Score
6.0/10
Composite research score
Smart Money
56/100
Neutral
Price performance · HLN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
HLN closed at $9.32 after 21 trading sessions, up 1.41% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $9.27 | $9.32 | $9.235 | $9.32 | 11.3M |
| Oct 8, 2026 | $9.10 | $9.26 | $9.08 | $9.26 | 20.28M |
| Oct 7, 2026 | $9.13 | $9.155 | $9.01 | $9.02 | 18.24M |
| Oct 6, 2026 | $8.95 | $8.955 | $8.825 | $8.87 | 12.84M |
| Oct 5, 2026 | $8.84 | $8.88 | $8.79 | $8.82 | 11.87M |
| Oct 2, 2026 | $8.79 | $8.81 | $8.71 | $8.80 | 22.39M |
| Oct 1, 2026 | $8.93 | $8.94 | $8.67 | $8.72 | 27.48M |
| Sep 30, 2026 | $9.13 | $9.145 | $8.995 | $9.00 | 17.75M |
| Sep 29, 2026 | $9.05 | $9.07 | $8.96 | $9.07 | 20.16M |
| Sep 28, 2026 | $9.13 | $9.19 | $9.11 | $9.17 | 15.71M |
| Sep 25, 2026 | $9.14 | $9.26 | $9.1122 | $9.26 | 22.37M |
| Sep 24, 2026 | $9.28 | $9.3485 | $9.20 | $9.22 | 16.84M |
| Sep 23, 2026 | $9.27 | $9.31 | $9.11 | $9.11 | 21.34M |
| Sep 22, 2026 | $9.35 | $9.393 | $9.235 | $9.25 | 29.49M |
| Sep 21, 2026 | $9.26 | $9.38 | $9.23 | $9.36 | 40.72M |
| Sep 18, 2026 | $9.20 | $9.325 | $9.20 | $9.28 | 45.17M |
| Sep 17, 2026 | $9.16 | $9.415 | $9.14 | $9.36 | 39.65M |
| Sep 16, 2026 | $9.25 | $9.31 | $9.20 | $9.21 | 9.31M |
| Sep 15, 2026 | $9.24 | $9.32 | $9.19 | $9.24 | 15.42M |
| Sep 14, 2026 | $9.41 | $9.44 | $9.32 | $9.39 | 13.82M |
| Sep 11, 2026 | $9.20 | $9.22 | $9.10 | $9.19 | 10.04M |
The latest Smart Investors Daily articles mentioning HLN.
Company
Market Activity
Research & News
HLN research
Company profile and research snapshot.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 1, 2026 | Deutsche | Sell | — |
| Jun 25, 2026 | JP Morgan Cazenove | Underweight | — |
| May 5, 2026 | Jefferies | Buy | — |
| Apr 30, 2026 | Berenberg Bank | Buy | — |
| Apr 30, 2026 | RBC Capital Markets | Sector Perform | — |
No generated briefing is available yet.
Yahoo · Oct 5, 2026
Goldman Sachs handpicks European stocks with the highest conviction for outperformance, and four of October's top selections carry a benefit most growth-focused investors overlook entirely.
Yahoo · Oct 3, 2026
Rising UK government bond yields have pushed up borrowing costs and sharpened the focus on where future productivity gains might come from. Artificial intelligence in healthcare offers one clear answer. It aims to cut waste, speed up diagnosis and make treatment more precise, which can matter when capital is not cheap. This article highlights three transformative AI healthcare stocks that showcase how this theme is playing out in practice. The stocks covered below are just a small sample of...
Yahoo · Sep 28, 2026
LCUT vs. HLN: Which Stock Is the Better Value Option?
Yahoo · Sep 28, 2026
Investing.com -- J.P. Morgan put “underweight” rated Haleon on negative Catalyst Watch ahead of its Oct. 29 results, saying third-quarter like-for-like sales growth is tracking at 3%, leaving the consumer health company at the bottom of its 3%-5% guidance range for a second straight year.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HLN.
